June 18, 2019

Robert J. Gould
President and Chief Executive Officer
Fulcrum Therapeutics, Inc.
26 Landsdowne Street
Cambridge, MA 02139

       Re: Fulcrum Therapeutics, Inc.
           Amendment No. 1 to Draft Registration Statement on Form S-1
           Submitted June 6, 2019
           CIK No. 0001680581

Dear Dr. Gould:

        We have reviewed your amended draft registration statement and have the
following
comment. In some of our comments, we may ask you to provide us with information
so we may
better understand your disclosure.

       Please respond to this letter by providing the requested information and
either submitting
an amended draft registration statement or publicly filing your registration
statement on
EDGAR. If you do not believe our comment applies to your facts and
circumstances or do not
believe an amendment is appropriate, please tell us why in your response.

      After reviewing the information you provide in response to the comment
and your
amended draft registration statement or filed registration statement, we may
have additional
comments. Unless we note otherwise, our references to prior comments are to
comments in our
May 28, 2019 letter.

Amendment No. 1 to DRS

Intellectual Property, page 126

1.     We note your response to prior comment 17 that you do not own any
patents. However,
       your disclosure continues to indicate that you own patents as you state
that the "patent
       portfolio for losmapimod is based upon Fulcrum-owned and in-licensed
patent families. .
       ." Please revise your disclosure accordingly, here and elsewhere as
appropriate, to remove
       any discrepancies.
 Robert J. Gould
FirstName LastNameRobert J. Gould
Fulcrum Therapeutics, Inc.
Comapany NameFulcrum Therapeutics, Inc.
June 18, 2019
Page 2
June 18, 2019 Page 2
FirstName LastName
       You may contact Mary Mast at 202-551-3613 or Mark Brunhofer at
202-551-3638 if
you have questions regarding comments on the financial statements and related
matters.
Please contact Dorrie Yale at 202-551-8776 or Joe McCann at 202-551-6262 with
any other
questions.



                                                        Sincerely,

                                                        Division of Corporation
Finance
                                                        Office of Healthcare &
Insurance
cc:      Lia Der Marderosian - WilmerHale